Recent Comments

Comment RSS

Lupus News and Research RSS Feed - Lupus News and Research

Systemic lupus erythematosus (SLE), also called lupus, is an autoimmune disorder characterized by the immune system attacking the body's own tissues and organs, leading to inflammation and damage. The severity of the disease varies, from mild cases only involving the skin to severe cases affecting multiple organs, including the brain. Lupus sufferers experience flares, or intervals of active disease, and remissions in disease. The disease most predominantly occurs in women of childbearing age, but also affects children, adolescents, and men. While the cause of lupus is still unknown, various genetic, environmental, and infectious causes have been associated with its development. Current treatments for lupus vary depending on the extent of the disease, and may change over time. Some medications used to ease symptoms include nonsteroidal anti-inflammatory drugs, antimalarial drugs, corticosteroids, and immunosuppressive medications, though many of these drugs carry their own risks.

SCF founder Sabrina Cohen recognized as a WebMD 2009 Health Hero

20. November 2009 08:04
Sabrina Cohen, founder of The Sabrina Cohen Foundation for Stem Cell Research (SCF), was just recognized as a WebMD 2009 Health Hero. She will receive national media attention with a full-page article about her personal story of triumph and courage, and shares the spotlight with celebrity movie-star, Scarlett Johansson and other Health Heroes in the November/December issue. [More]

Posted in: Medical Science News | Miscellaneous News

Tags: , , , , , , ,

Final results from ImmuPharma's Phase IIb trial of LUPUZOR

19. November 2009 03:50
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , ,

Protein content of women's saliva changes with advancing age, describe scientists

19. November 2009 01:26
In a step toward using human saliva to tell whether those stiff joints, memory lapses, and other telltale signs of aging are normal or red flags for disease, scientists are describing how the protein content of women's saliva change with advancing age. [More]

Posted in: Medical Science News | Women's Health News

Tags: , , ,

Johns Hopkins University to create a Human Proteome Chip using Arrayit's technology

18. November 2009 07:41
Arrayit Corporation announced today that the new High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to create a Human Proteome Chip to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis (first identified by Dr. Zhu), lupus, and others. [More]

Cold weather can trigger Raynaud's disease

17. November 2009 01:53
Cold weather triggers a painful and sometimes debilitating disorder for millions of Americans who suffer from Raynaud's disease (also known as Raynaud's syndrome or phenomenon). Raynaud's is an autoimmune disorder in which spasms in the blood vessels can interrupt blood flow to the fingers, toes, nose and ears. Exposure to cold triggers the spasms, typically causing the affected area to turn white, then blue, then bright red. Emotional stress can also cause an attack. [More]

Posted in: Medical Condition News

Tags: , , , , , , ,

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

16. November 2009 07:53
Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA. [More]

Tips for treating age-related dermatologic concerns

11. November 2009 02:58
Everyone expects their bodies to change as they get older. From wrinkles and sagging skin to brittle bones and aches and pains, the aging process is inevitable. In addition, there are a number of medical dermatologic conditions that surface with age that can cause people even more stress. Fortunately, dermatologists can help diagnose and treat these conditions no matter when they strike. [More]

Reportlinker's new report on the global stem cell and advanced technologies market

11. November 2009 01:36
The stem cell market is growing rapidly due to increasing regulatory approval and public acceptance bodies. The benefits of stem cell therapy are attracting an increasing number of patients. The product submarket for human and embryo stem cells are expected to drive the growth of the overall market. In addition, intensive R&D efforts and the increasing investments into research on stem cells therapy are soon expected to improve the efficacy of stem cell treatment. However, the high cost of the therapy may affect market growth. [More]

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

7. November 2009 01:23
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , ,

Study on asbestos-related diseases in Libby launched

4. November 2009 05:00
Over nearly a century, thousands of residents and workers in Libby, MT, have been exposed to asbestos-contaminated vermiculite ore, leading to markedly higher rates of lung disease and autoimmune disorders, and causing to Libby in 2002 to be added to the federal Environmental Protection Agency's "National Priorities List." [More]

Posted in: Medical Condition News

Tags: , , , , , , , , ,

Smokers with SLE at greater risk of skin damage and rashes

3. November 2009 06:07
As if there weren't enough reasons to stop smoking, a team of researchers at the Research Institute of the McGill University Health Centre (RI-MUHC) have just found another. A study led by Dr. Christian A Pineau, Co-Director of the Lupus and Vasculitis clinic at the MUHC, has clearly linked skin damage and rashes to smoking in people with systemic lupus erythematosus (SLE). The study was published in a recent issue of the Journal of Rheumatology. [More]

Interim data from Schering-Plough's narlaprevir Phase IIa study

3. November 2009 03:02
Schering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. [More]

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

2. November 2009 08:54
SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States. [More]

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

2. November 2009 04:07
The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , ,

HGS and GSK announce results from phase III clinical trials of BENLYSTA

2. November 2009 03:32
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA). [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.